This is a published notice on the Find a Tender service: <a href="https://www.find-tender.service.gov.uk/Notice/023588-2021">https://www.find-tender.service.gov.uk/Notice/023588-2021</a>

#### **Planning**

# Procurement for neutralising antibodies

Department of Health and Social Care

F01: Prior information notice

Prior information only

Notice identifier: 2021/S 000-023588

Procurement identifier (OCID): ocds-h6vhtk-02e397

Published 22 September 2021, 3:20pm

## **Section I: Contracting authority**

### I.1) Name and addresses

Department of Health and Social Care

39 Victoria Street

London

SW1H 0EU

#### **Contact**

Amjad Kazmi

#### **Email**

amjad.kazmi@dhsc.gov.uk

#### Country

**United Kingdom** 

#### **NUTS** code

UKI32 - Westminster

#### Internet address(es)

Main address

https://www.gov.uk/government/organisations/department-of-health-and-social-care

Buyer's address

https://www.gov.uk/government/organisations/department-of-health-and-social-care

## I.3) Communication

Additional information can be obtained from the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

http://health.atamis.co.uk

### I.4) Type of the contracting authority

Ministry or any other national or federal authority

## I.5) Main activity

Health

## **Section II: Object**

## II.1) Scope of the procurement

#### II.1.1) Title

Procurement for neutralising antibodies

#### II.1.2) Main CPV code

• 33600000 - Pharmaceutical products

#### II.1.3) Type of contract

Supplies

#### II.1.4) Short description

DHSC invites suppliers to provide information on neutralising antibodies and binding site, clinical trials on efficacy, safety for preventing or treating COVID-19 infection, dose&frequency, formats/routes for administering to patients, monitoring adverse affects, efficacy against SARS-CoV-2 variants, supply availability for 2021-2022 and future years and plans for regulatory approval in the UK, if not yet approved.

#### II.1.5) Estimated total value

Value excluding VAT: £1

#### II.1.6) Information about lots

This contract is divided into lots: No

### II.2) Description

#### II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

**NUTS** codes

UKI32 - Westminster

Main site or place of performance

#### **United Kingdom**

#### II.2.4) Description of the procurement

The Department is interested in engaging with the emerging market prior to the publication of a contract notice to find innovative neutralising antibody COVID-19 therapies that could inform the specification of requirements, conditions of contract and commercial model. Further details of how suppliers may engage with the Department are included in section VI.3) (additional information) at the end of this notice.

### II.2.14) Additional information

Interested parties should submit questions via Atamis. Department welcomes discussions with interested parties on areas provision of a value for money solution for the UK tax payer; creating mechanisms for money solution for the UK tax payer; creating mechanisms (including but not limited to agreements) to secure long-term, guaranteed supply contracts with 'step-in' rights in future pandemics

### II.3) Estimated date of publication of contract notice

22 September 2021

#### Section IV. Procedure

### IV.1) Description

#### IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

## Section VI. Complementary information

## VI.3) Additional information

This Prior Information Notice has been issued to alert the market for the possible procurement of neutralising antibodies.